Last reviewed · How we verify
Placebo matched to SC0062
Placebo matched to SC0062 is a Small molecule drug developed by Biocity Biopharmaceutics Co., Ltd.. It is currently in Phase 3 development.
This is a placebo control formulation matched to SC0062, containing no active pharmaceutical ingredient.
At a glance
| Generic name | Placebo matched to SC0062 |
|---|---|
| Sponsor | Biocity Biopharmaceutics Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo matched to SC0062, this product is designed to be indistinguishable from the active investigational drug SC0062 in appearance, taste, and administration route, allowing for blinded comparison in clinical trials. It contains no active ingredient and serves as a control to isolate the therapeutic effect of SC0062 from placebo response.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matched to SC0062 CI brief — competitive landscape report
- Placebo matched to SC0062 updates RSS · CI watch RSS
- Biocity Biopharmaceutics Co., Ltd. portfolio CI